Japan Eli Lilly signs a joint research agreement on obesity countermeasures with the Japan Institute for Health Security and the National Cerebral and Cardiovascular Center
Summary
Japan Eli Lilly has signed a joint research agreement with the Japan Institute for Health Security and the National Cerebral and Cardiovascular Center to advance obesity treatment measures. The collaboration will strengthen an industry-government-academia framework for research, clinical practice, education, and public understanding of obesity as a chronic disease. The partners will launch studies on the real-world effectiveness of obesity drug treatment, the mechanisms behind obesity-related complications, and the role of adipokines in cardiovascular disease and organ aging. Lilly also says it plans to expand similar joint research with other national medical research centers in the future. The agreement supports evidence building that could influence care models, health policy, and clinical decision-making in Japan.